Several stock analysts who follow drug companies said physicians will switch patients to Celebrex in short term.
Celebrex is picking up some of slack.
Pharmaceutical giant Merck on Friday disputed conclusion of the British medical weekly The Lancet that the arthritis drug Vioxx should have been pulled from the market four years earlier.
Many analysts and doctors believe Arcoxia will only be approved after that study is completed and it demonstrates the drug doesn't increase the risk of heart attacks and strokes The 7,111-patient trial that was presented Tuesday at the American College of Rheumatology's annual meeting in San Antonio.
